Welcome to our dedicated page for Crinetics Pharmaceuticals SEC filings (Ticker: CRNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Crinetics Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Crinetics Pharmaceuticals's regulatory disclosures and financial reporting.
Crinetics Pharmaceuticals, Inc. (CRNX) submitted a Form 144 notice for the proposed sale of securities. The filer intends to sell 4,000 shares of Common stock through UBS Financial Services Inc. (11 Madison Ave, New York) with an aggregate market value of $180,000. The approximate date of sale is 09/26/2025 on NASDAQ. The shares were acquired as Founder Shares from the issuer on 07/31/2011, and full payment was recorded on that date. The filing reports nothing to report for securities sold during the past three months. Other standard notice fields (such as a signed date of notice) are present as headers but no explicit signature date or contact details are provided in the text supplied.
Crinetics Pharmaceuticals announced that the U.S. Food and Drug Administration approved PALSONIFY™ (paltusotine) on September 25, 2025 for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY is described as a selectively-targeted somatostatin receptor type 2 nonpeptide agonist and is now the first once-daily, oral treatment approved for adults with acromegaly. Crinetics is also holding an investor conference call on September 25, 2025 to discuss the approval, and a press release and call replay will be available in the investors section of its website.
Farallon Capital and affiliated funds disclosed collective holdings in Crinetics Pharmaceuticals (CRNX). The Schedule 13G shows multiple Farallon funds and related entities beneficially own reported positions in the issuer's common stock. The largest single reported beneficial owner line is 5,625,098 shares (6.0% of the class) attributable to the group of Farallon Individual Reporting Persons acting with shared voting and dispositive power. Other reported aggregates include 5,482,921 shares (5.8%) for Farallon Partners, L.L.C. and 3,305,391 shares (3.5%) for Farallon Healthcare Partners Master, L.P. Each reporting person reports 0 sole voting power and varying shared voting/dispositive power. The filing is made under Section 240.13d-1(c) and includes signed certifications dated 09/08/2025.
Crinetics Pharmaceuticals (CRNX) reporting insider transactions by Dana Pizzuti. The filing shows on 09/02/2025 the reporting person acquired 5,000 shares of common stock by exercising options at an exercise price of $16.89 and simultaneously sold 5,000 shares in open-market transactions under a Rule 10b5-1 plan at a volume-weighted average price of $32.10 per share (range $32.00–$32.24). Following these transactions the reporting person beneficially owned 96,270 shares of common stock and directly held 84,042 shares underlying vested and unvested stock options that remain outstanding. The sale was effected automatically pursuant to a 10b5-1 trading plan adopted May 21, 2025.
Form 144 notice for Crinetics Pharmaceuticals, Inc. (CRNX) reports a proposed sale of 5,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $154,950.00. The shares were acquired and will be paid for by exercise of stock options on 09/02/2025 and sale is expected the same date on NASDAQ. The filing also discloses recent 10b5-1 sales by Dana Pizzuti totaling 36,492 shares for gross proceeds of $1,102,425.82 executed on 08/20/2025 and 08/22/2025. The filer affirms no undisclosed material adverse information.
Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, executed transactions on 08/22/2025 reported on this Form 4. The filing discloses an exercise of a stock option to acquire 30,000 shares at an exercise price of $16.89 per share and an open-market sale of 30,000 shares executed under a Rule 10b5-1 trading plan adopted May 21, 2025.
The sale had a volume-weighted average price of $30.43 per share and a transaction-day price range of $30.00 to $30.98. Following the transactions the reporting person shows 66,270 shares beneficially owned directly and reports 30,000 underlying shares from the option; the Form lists 89,042 derivative securities beneficially owned following the reported transactions. The sale was effected automatically pursuant to the 10b5-1 plan.
Crinetics Pharmaceuticals (CRNX) filed a Form 144 disclosing a proposed sale of 30,000 shares of Common stock through Morgan Stanley Smith Barney with an aggregate market value of $882,000, to be sold on 08/22/2025 on NASDAQ. The shares were reported acquired that same day on 08/22/2025 by exercise of stock options from the issuer, with cash payment reported for the option exercise.
The filing also lists prior 10b5-1 sales by Dana Pizzuti of 6,492 shares on 08/20/2025 generating gross proceeds of $189,426.82. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Insider sale by Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals (CRNX). On 08/20/2025 Ms. Pizzuti sold 6,492 shares of Crinetics common stock in open-market transactions at a volume-weighted average price of $29.18 per share, with the intraday price range $28.94 to $29.47. The sale was effected automatically under a Rule 10b5-1 trading plan adopted May 21, 2025.
Following the reported transactions she beneficially owned 66,270 shares, which includes 529 shares acquired under the companys Employee Stock Purchase Plan. The Form 4 was signed by an attorney-in-fact on 08/21/2025.
Crinetics Pharmaceuticals (CRNX) filed a Form 144 reporting a proposed sale of 6,492 common shares valued at $191,059.56 with an approximate sale date of 08/20/2025 on NASDAQ. The filing lists total shares outstanding of 94,175,994. The securities were acquired as 4,360 restricted stock units on 03/15/2025 and 2,132 shares through an employee stock purchase plan on 05/20/2023. The filer reports no securities sold in the past three months. Several standard filer contact and issuer identification fields in the provided content are blank or not provided.
Wellington Management reporting persons disclose beneficial ownership of 5,807,308 shares of Crinetics Pharmaceuticals common stock, representing 6.2% of the class. The stake is reported across multiple Wellington entities (holding companies and investment advisers) and is held of record by clients of the Wellington investment advisers.
The filing shows no sole voting or dispositive power reported by the filers and reports shared voting power and shared dispositive power across the Wellington entities. The filers certify the securities are held in the ordinary course of business and not for the purpose of changing control.